SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Divi's Laboratories reports 21% rise in consolidated net profit in Q1

03 Aug 2024 Evaluate

Divi's Laboratories has reported results for first quarter ended June 30, 2024 (Q1FY25). 

The company has reported 24.63% rise in net profit at Rs 430 crore for Q1FY25 as compared to Rs 345 crore for the same quarter in the previous year. Total income of the company increased by 18.34% at Rs 2142 crore for Q1FY25 as compared to Rs 1810 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 20.78% rise in its net profit at Rs 430 crore for the quarter ended June 30, 2024 as compared to Rs 356 crore for the same quarter in the previous year. Total income of the company increased by 18.18% at Rs 2197 crore for Q1FY25 as compared to Rs 1859 crore for the corresponding quarter previous year.

Divis Lab Share Price

6281.35 52.40 (0.84%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×